Connect with us
Finance Digest is a leading online platform for finance and business news, providing insights on banking, finance, technology, investing,trading, insurance, fintech, and more. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Research Reports

The global Rheumatoid Arthritis Treatment Market is expected to stimulate at a good rate In Upcoming Years. Virtual consultations are amongst the ongoing trends. They mitigate the spreading of contagious ailments, thereby facilitating better efficiency. The gap regarding the demand-supply ratio could also be bridged this way. With this practice being followed, the developing economies would benefit better, as the cost to commute could be curtailed.

Rising occurrence of rheumatoid arthritis because of shift toward unhealthy lifestyle as well as increasing research & development activities for better and permanent therapy alternatives for rheumatoid arthritis treatment in order to diminish repeat rates are supporting market development. Rheumatoid arthritis is related with the immune system that leads to inflammation in the joints of the body, and later on the disease affects the muscles, fibrous tissues, tendons, and connective tissues.

launching technologically advanced products and receiving approval from different government bodies.

Planning Forward? Access Sample of Rheumatoid Arthritis Treatment Market Report@

The load of rheumatoid arthritis (RA), currently incurable and an unending autoimmune disease that basically attacks the joints, is prominent. In 2020, approximately 4.9 million individuals across major regions were affected by rheumatoid arthritis. Manufacturers are focusing on partnerships and expansion of product portfolio by launching technologically advanced products and receiving approval from different government bodies.

The global rheumatoid arthritis treatment market is estimated to be valued at US$ 40.5 Bn in 2021, and is expected to exhibit a CAGR of around 6% over the forecast period (2021 – 2031).

Company Profiles:

  • Sanofi SA
  • Pfizer Inc.
  • AbbVie Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffman-La Roche AG
  • Teva Pharmaceuticals, Inc.
  • Cipla, Inc.
  • Dr. Reddy’s Laboratories
  • Sun Pharmaceutical Industries Ltd.
  • Roxane Laboratories Inc,
  • Amneal Pharmaceuticals LLC.
  • Sobi Inc.
  • Norbrook Laboratories Ltd.

Get A Customized Scope To Match Your Need Ask An Expert –

How About Re-Inventing The Methodical Wheel In The Rheumatoid Arthritis Treatment Market? Switch Over To The “Methodology” Tab!

Key Takeaways from Market Study

“Rise in prevalence of rheumatoid arthritis along with increase in adoption of DMARD therapies, flourishing combination treatment, and supportive government policies are expected to drive market growth,” says a Persistence Market Research analyst.

Collaborations and Acquisitions – Imperative Strategy for Market Players

Major companies in the rheumatoid arthritis treatment market are actively engaging in acquisitions and expansions in order to enhance their product portfolios and outreach to a large number of customers. Globally, leading companies are acquiring other companies who are facing a large number of product recalls in the market.

  • In April 2021, Novartis signed an initial agreement with Roche to reserve capacity and implement technology transfer for the production of active pharmaceutical ingredient (API) for Roche’s Actemra/RoActemra® (tocilizumab), a treatment for rheumatoid arthritis, which is also being tested in various clinical trials investigating the safety and efficacy in COVID-19-associated pneumonia.
  • In October 2020, Johnson & Johnson announced successful acquisition of Momenta Pharmaceuticals, Inc. (“Momenta”), a company that discovered and developed novel therapies for immune-mediated diseases.

Planning To Introduce An Offbeat Product/Technology In The Rheumatoid Arthritis Treatment Market? Go To “Purchase Now” To Have Our Rheumatoid Arthritis Treatment Market Report!

COVID-19 Crisis Impact

Due to the unprecedented pandemic scenario, the healthcare sector has been the central point across regions. As import activities were halted, this adversely affected the finances of a majority of healthcare companies. Every industry, including healthcare, is suffering from supply chain disruptions.

The World Health Organization (WHO) declared the COVID-19 outbreak a public health emergency of international significance on January 30, 2020. Around 210 countries have been affected by COVID-19. Patients with rheumatoid arthritis who contract COVID-19 infection, according to the Lancet Rheumatology 2020, are at a high risk of experiencing serious symptoms and complications.

Some DMARDs commonly used to treat rheumatoid arthritis, such as hydroxychloroquine drugs, are being investigated as potential therapy for COVID-19. Moreover, other generally used therapies such as biologics targeting interleukin (IL)-6 (sarilumab, tocilizumab) and IL-1 (anakinra) are being assessed in patients with COVID-19. Thus, COVID-19 infection uplifted growth opportunities for manufacturers of rheumatoid arthritis drugs. For instance,

  • Tocilizumab, a drug originally used for rheumatoid arthritis, is seeing increased use in treating severe COVID-19 patients.
  • A drug developed for rheumatoid arthritis by global pharma company Roche is licensed exclusively to Indian pharma company Cipla.

What else is in the report?

Persistence Market Research offers a unique perspective and actionable insights on the rheumatoid arthritis treatment market in its latest study, presenting historical demand assessment of 2016 – 2020 and projections for 2021–2031, based on therapy (symptomatic treatment, intermediate corticosteroid therapies, stem cell therapy/ cell therapy, and disease modifying anti-rheumatic drugs (DMARDs)) and distribution channel (hospital pharmacies, retail pharmacies, and drug stores), across seven key regions of the world.

Related Reports:

Dysphagia Supplements Market 

Uveitis Treatment Market

About Us: Persistence Market Research

Contact Us:

Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353

Japan Office: 1-2-1 Kinshi Arca Central Building
14/F Tokyo, 130-0013, Japan
Call 1-888-863-3700

Sales –
Website –

Continue Reading

Why pay for news and opinions when you can get them for free?

       Subscribe for free now!

By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Recent Posts